The link you have selected will take you to a site outside xeneticbio.com.

Xenetic Biosciences, Inc. does not review or control the content of any non-Xenetic Biosciences, Inc. site. Xenetic Biosciences, Inc. does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Xenetic Biosciences, Inc. sites.

Xenetic Biosciences, Inc.

menu
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partners
    • Careers
  • Technology
    • DNase I Oncology Platform
    • Publications
  • Pipeline
    • Overview
    • XBIO-015
    • XBIO-020
  • News & Media
    • Press Releases
    • Presentations
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
News & Media

News & Media

  • Press Releases
  • Presentations

Press Releases

  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Jan 17, 2024

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Nov 10, 2023

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Oct 11, 2023

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

Aug 11, 2023

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

Jul 5, 2023

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

May 12, 2023

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development

May 4, 2023

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

May 3, 2023
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...17
  • Next »

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2025Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap